晚期前列腺癌采用内分泌药物治疗的疗效观察

孙维

【摘要】 目的 分析對于晚期前列腺癌患者， 采用内分泌药物治疗的临床效果。方法 选择行手术治疗的晚期前列腺癌患者100例， 根据术后给予内分泌药物不同分为A组、B组， 每组50例， A组术后给予比卡鲁胺， B组术后给予氟他胺;选择同期单纯实施手术治疗的50例患者作为对照组， 术后不给予内分泌药物治疗。比较三组患者临床症状缓解情况及治疗前后前列腺特异抗原（PSA）水平、前列腺体积， 随访1年复发情况。结果 治疗后， A组患者临床症状缓解率为80.00%;B组患者临床症状缓解率为82.00%;对照组患者临床症状缓解率为60.00%。A组、B组患者的临床症状缓解率均明显高于对照组， 差异具有统计学意义（P<0.05）;A组、B组患者的临床症状缓解率比较， 差异无统计学意义（P>0.05）。治疗后， A组、B组患者的PSA水平均低于对照组， 差异有统计学意义（P<0.05）;A组、B组患者的PSA水平比较差异无统计学意义（P>0.05）。随访1年， A组出现生化复发5例， 复发率为10.00%;B组出现生化复发6例， 复发率为12.00%;对照组出现生化复发14例， 复发率为28.00%。A组、B组患者的复发率均低于对照组， 差异具有统计学意义（P<0.05）。治疗后， 三组患者前列腺体积均小于本组治疗前， 差异具有统计学意义（P<0.05）;三组患者前列腺体积比较差异无统计学意义（P>0.05）。结论 晚期前列腺癌患者术后给予比卡鲁胺以及氟他胺治疗的效果较为理想， 可以降低复发率， 改善患者术后情况。

【关键词】 晚期前列腺癌;内分泌药物;疗效

【Abstract】 Objective   To analyze the clinical effect of endocrine drug therapy for patients with advanced prostate cancer. Methods   A total of 100 patients with advanced prostate cancer undergoing surgical treatment were divided into group A and group B according to different endocrine drugs given after operation， with 50 cases in each group. Group A was treated with bicalutamide， and group B was treated with flutamide. 50 patients who underwent surgery alone at the same time were selected as control group， and no endocrine drugs were given after operation. Comparison was made on remission status of clinical symptoms， prostate specific antigen （PSA） level and prostate volume before and after treatment， and recurrence status after 1-year follow-up between the two groups. Results   After treatment， the remission rate of clinical symptoms was 80.00% in group A， and that was 82.00% in group B and 60.00% in the control group. The remission rate of clinical symptoms in group A and group B was obviously higher than that in the control group， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in remission rate of clinical symptoms in group A and group B （P>0.05）. After treatment， the PSA level in group A and group B was lower than that in the control group， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in PSA level in group A and group B （P>0.05）. After 1-year follow-up， there was 5 cases of biochemical recurrence in group A， with recurrence rate as 10.00%; 6 cases of biochemical recurrence in group B， with recurrence rate as 12.00%; 14 cases of biochemical recurrence in the control group， with recurrence rate as 28.00%. The recurrence rate in group A and group B was lower than that in the control group， and the difference was statistically significant （P<0.05）. After treatment， the prostate volume in three groups was smaller than those before treatment， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in prostate volume in three groups （P>0.05）. Conclusion   Bicalutamide and flutamide shows ideal effect for patients with advanced prostate cancer， and it can reduce the recurrence rate and improve the postoperative condition of patients.